>Mercado europeu de tratamento de terapia celular CAR-T, por produto (células CAR-T autólogas, células CAR-T alogénicas), estrutura (células CAR-T de primeira geração, células Car-T de segunda geração, células CAR-T de terceira geração, quarta geração Células CAR-T), antigénios dirigidos (antigénios em tumores sólidos, antigénios em doenças malignas hematológicas, outros), marca (Yescarta, Kymriah, Tecartus, outros), aplicação terapêutica (malignidades hematológicas, cancro do pâncreas, cancro da mama, cancro do pulmão, cancro gástrico , Mieloma Múltiplo, Leucemia Linfocítica Crónica, Linfoma de Células do Manto, Linfoma Folicular, Linfoma Difuso de Grandes Células B, Leucemia Linfoblástica Aguda, Outros), Utilizador Final (Hospitais, Clínicas Especializadas, Outros) , Canal de Distribuição (Hospitais de Farmácia, Outros), País (Alemanha, Reino Unido, França, Itália, Espanha, Países Baixos, Rússia, Suíça, Turquia, Áustria, Noruega, Hungria, Lituânia, Irlanda, Polónia, Resto da Europa) Tendências e previsões da indústria para 2028
Análise de mercado e insights : Mercado europeu de tratamento de terapia celular CAR-T
Espera-se que o mercado de tratamento de terapia celular CAR-T ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 29,4% no período de previsão de 2021 a 2028 e prevê-se que atinja os 10.594,65 milhões de dólares até 2028. Aumento da utilização da terapia com células CAR-T para o tratamento do cancro e doenças infeciosas atuando como impulsionador para o crescimento do mercado de tratamento com terapia com células CAR-T.
A terapia com células CAR-T ou células T recetoras de antigénios quiméricos são aquelas células T que são geneticamente modificadas para produzir um recetor artificial de células T que pode ser utilizado como imunoterapia para o tratamento de vários tipos de cancro. Os recetores de antigénios quiméricos são aquelas proteínas recetoras que foram concebidas em laboratórios para fornecer às células T a nova capacidade de atingir uma proteína específica.
O aumento da consciencialização sobre as imunoterapias levou as pessoas a depararem-se com diversos tipos de terapias CAR-T e a sua eficácia e, portanto, a atuarem como impulsionadores do mercado de tratamento da terapia com células CAR-T. Os efeitos secundários adversos das terapias restringem alguma população a optar por tal tratamento que impacta o valor do produto e, portanto, atua como restrição para o crescimento do mercado de tratamento de terapia celular CAR-T. A presença de produtos em pipeline sugere que os players do mercado estão constantemente envolvidos no fabrico de medicamentos inovadores, atuando assim como uma oportunidade para o mercado de tratamento de terapia celular CAR-T. O longo tempo de aprovação para imunoterapias restringe o fabricante do produto a obter potenciais benefícios no mercado e impacta o tamanho geral do mercado, pelo que atua como um desafio para o crescimento do mercado de tratamento de terapia celular CAR-T.
O relatório de mercado de tratamento de terapia celular CAR-T fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa oportunidades em termos de bolsas de receitas emergentes, mudanças nas regulamentações de mercado, aprovações de produtos, decisões estratégicas. , lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado contacte-nos para um resumo do analista, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.
Âmbito do mercado de tratamento de terapia celular CAR-T da Europa e dimensão do mercado
O mercado de tratamento de terapia celular CAR-T está segmentado com base no produto, estrutura, antigénios direcionados, marca, aplicação terapêutica, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base no produto, o mercado de tratamento de terapia celular CAR-T está segmentado em células CAR-T autólogas e células CAR-T alogénicas. Em 2021, prevê-se que o segmento de células CAR-T autólogas domine o mercado de tratamento de terapia com células CAR-T porque os medicamentos aprovados para a terapia com células CAR-T são de natureza autóloga.
- Com base na estrutura, o mercado de tratamento de terapia celular CAR-T está segmentado em células CAR-T de primeira geração, células CAR-T de segunda geração, células CAR-T de terceira geração e células CAR-T de quarta geração. Em 2021, prevê-se que o segmento de células CAR-T de segunda geração domine o mercado de tratamento de terapia celular CAR-T porque as terapias aprovadas são estruturas baseadas na segunda geração.
- Com base em antigénios direcionados, o mercado de tratamento de terapia celular CAR-T está segmentado em antigénios em tumores sólidos, antigénios em malignidades hematológicas e outros. Em 2021, espera-se que os antigénios no segmento das neoplasias hematológicas dominem o mercado de tratamento de terapia com células CAR-T porque os medicamentos aprovados para a terapia com células CAR-T são utilizados principalmente para neoplasias hematológicas e um extenso desenvolvimento de investigação em curso.
- Com base na marca, o mercado de tratamento de terapia celular CAR-T está segmentado em yescarta, kymriah, tecartus e outros. Em 2021, prevê-se que o segmento yescarta domine o mercado de tratamento de terapia com células CAR-T porque yescarta é a primeira terapia com células CAR-T aprovada para a classe terapêutica oncológica.
- Com base na aplicação terapêutica, o mercado de tratamento de terapia celular CAR-T está segmentado em malignidades hematológicas, cancro do pâncreas , cancro da mama, cancro do pulmão, cancro gástrico, mieloma múltiplo , leucemia linfocítica crónica, linfoma de células do manto, linfoma folicular, grande difuso B -linfoma celular, leucemia linfoblástica aguda e outros. Em 2021, prevê-se que o segmento das neoplasias hematológicas domine o mercado de tratamento de terapia com células CAR-T porque o yescarta representa a maior receita do mercado e o linfoma folicular é a principal indicação para o yescarta.
- Com base no utilizador final, o mercado de tratamento de terapia celular CAR-T está segmentado em hospitais , clínicas especializadas e outros. Em 2021, o segmento hospitalar está a dominar o mercado de tratamento de terapia com células CAR-T porque a terapia com células CAR-T exigia profissionais altamente treinados com laboratórios de tecnologia avançada.
- Com base no canal de distribuição, o mercado de tratamento de terapia celular CAR-T está segmentado em farmácias hospitalares e outras. Em 2021, prevê-se que o segmento das farmácias hospitalares domine o canal de distribuição de tratamento de terapia celular CAR-T porque as farmácias hospitalares são a parte central dos hospitais, todos os produtos relacionados com infusões e medicamentos vendidos pelo departamento de farmácia.
Análise ao nível do país do mercado de tratamento de terapia celular CAR-T
O mercado de tratamento de terapia celular CAR-T é analisado e são fornecidas informações sobre o tamanho do mercado com base no país, produto, estrutura, antigénios direcionados, marca, aplicação terapêutica, utilizador final e canal de distribuição como mencionado acima.
Os países abrangidos no relatório europeu do mercado de tratamento de terapia celular CAR-T são Alemanha, Reino Unido, França, Itália, Espanha, Países Baixos, Rússia, Suíça, Turquia, Áustria, Noruega, Hungria, Lituânia, Irlanda, Polónia e Resto da Europa .
O segmento de células CAR-T autólogas na Alemanha está a dominar o mercado europeu de tratamento de terapia com células CAR-T devido à prevalência do cancro.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, a presença e a disponibilidade das marcas europeias e os desafios enfrentados devido à grande ou escassa concorrência das marcas locais e nacionais, o impacto dos canais de vendas são considerados, ao mesmo tempo que se fornecem uma análise de previsão dos dados do país.
O aumento da consciencialização sobre as imunoterapias está a impulsionar o crescimento do mercado de tratamento de terapia celular CAR-T
O mercado de tratamento de terapia celular CAR-T também fornece análises de mercado detalhadas para o crescimento de cada país na indústria de tratamento de terapia celular CAR-T com vendas de tratamento de terapia celular CAR-T, impacto do avanço na tecnologia de tratamento da terapia celular CAR-T e mudanças nos cenários regulamentares com o seu apoio ao mercado de tratamento da terapia celular CAR-T. Os dados estão disponíveis para o período histórico de 2011 a 2019.
Análise do panorama competitivo e da quota de mercado do tratamento de terapia celular CAR-T
O panorama competitivo do mercado de tratamento de terapia celular CAR-T fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produtos, aprovações de produtos, patentes, largura do produto e respiração, domínio da aplicação, curva da linha de vida da tecnologia. Os dados acima fornecidos estão apenas relacionados com o foco da empresa relacionado com o mercado de tratamento de terapia celular CAR-T.
As principais empresas que estão a negociar no relatório de mercado de tratamento de terapia celular CAR-T são Autolus, Amgen Inc., bluebird bio, Inc., Adaptimmune Therapeutics plc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc, AbbVie Inc. , Novartis AG, Kite Pharma (uma subsidiária da Gilead Sciences, Inc.), Cellectis, TC BIOPHARM, Celyad Oncology, entre outros players nacionais e globais. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.
Muitos lançamentos de produtos e acordos são também iniciados pelas empresas de todo o mundo, que também estão a acelerar o mercado de tratamento de terapia celular CAR-T.
Por exemplo,
- Em dezembro de 2020, a Atara Biotherapeutics, Inc. colaborou com a Bayer AG para o desenvolvimento de terapias de células T CAR dirigidas à mesotelina para tumores sólidos. De acordo com o acordo, a empresa está altamente focada no desenvolvimento do ATA2271 para tratar o mesotelioma pleural maligno e o cancro do pulmão de células não pequenas. Esta colaboração acelerou a investigação e o desenvolvimento da empresa para o ATA2271 e permitiu-lhe tornar-se o principal fabricante de terapia com células CAR-T alogénicas.
A colaboração, o lançamento de produtos, a expansão do negócio, a premiação e o reconhecimento, as joint ventures e outras estratégias dos players do mercado estão a melhorar o mercado da empresa no mercado de tratamento de terapia celular CAR-T, que também oferece o benefício para a organização melhorar a sua oferta de CAR-T tratamento com terapia celular.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
- introduction
- OBJECTIVES OF THE STUDY
- MARKET DEFINITION
- OVERVIEW of EUROPE CAR-T cell therapy treatment MARKET
- LIMITATIONs
- MARKETS COVERED
- MARKET SEGMENTATION
- MARKETS COVERED
- geographical scope
- years considered for the study
- currency and pricing
- DBMR TRIPOD DATA VALIDATION MODEL
- MULTIVARIATE MODELLING
- PRODUCT LIFELINE CURVE
- primary interviews with key opinion leaders
- DBMR MARKET POSITION GRID
- vendor share analysis
- MARKET product COVERAGE GRID
- secondary sourcEs
- assumptions
- EXECUTIVE SUMMARY
- premium insight
- Epidemiology
- Pipeline analysis
- Market Overview
- Drivers
- increase in usage of CAR-T CELL THERAPY for the treatment of cancer and infectious diseases
- increasing prevalEnce of cancer
- rise in awareness about immunotherapies
- increasing investment in research and development
- adoption of CAR-T cell therapy treatment in Emerging markets
- restraints
- adverse side effects of therapies
- high cost associated with therapies
- logistic challenge associated with CAR-T therapies
- availability of alternatives for tumor treatment
- opportunities
- presence of pipeline producTs
- strategiC initiatives by market players
- Rise in expenditure in healthcare sector
- challenges
- long approval time for immunotherapies
- lack of skilled professionals
- IMPACT OF COVID-19 ON EUROPE CAR-T CELL THERAPY TREATMENT MARKET
- IMPACT ON PRICE
- IMPACT ON DEMAND
- IMPACT ON SUPPLY CHAIN
- STRATEGIC DECISION FOR MANUFACTURERS
- CONCLUSION
- Europe CAR-T Cell Therapy Treatment MARKET, BY PRODUCT
- overview
- Autologous CAR-T Cells
- Allogeneic CAR-T Cells
- Europe CAR-T CELL THERAPY TREATMENT MARKET, BY Structure
- overview
- First Generation CAR-T Cells
- Second Generation CAR-T Cells
- Third Generation CAR-T Cells
- Fourth Generation CAR-T Cells
- Europe CAR-T CELL THERAPY TREATMENTMARKET, BY Targeted Antigens
- overview
- Antigens on Hematologic Malignancies
- Cluster of Differentiation-19 (CD-19)
- Cluster of Differentiation-30 (CD-30)
- Cluster of Differentiation-22 (CD-22)
- Cluster of Differentiation-20 (CD-20)
- Cluster of Differentiation-33 (CD-33)
- Antigens on Solid Tumors
- Human Epidermal Growth Factor Receptor-2 (HER-2)
- Epidermal Growth Factor Receptors Variant III (EGFRV-III)
- Mesothelin (MSLN)
- Prostate-Specific Membrane Antigen (PSMA)
- Interleukin-13RA2 (IL13RA2)
- Disialoganglioside 2 (GD2)
- Glypican-3 (GPC3)
- Others
- OTHERS
- Europe CAR-T cell therapy treatment MARKET, BY brand
- overview
- yescarta
- KYMRIAH
- TECARTUS
- others
- Europe CAR-T cell therapy treatment MARKET, BY therapeutic application
- overview
- Follicular Lymphoma
- Diffuse Large B-Cell Lymphoma
- Acute Lymphoblastic Leukaemia (ALL)
- Mantle Cell Lymphoma
- Multiple Myeloma
- Hematologic Malignancies
- Leukemia
- Lymphoma
- Myeloma
- Others
- Lung Cancer
- Chronic Lymphocytic Leukemia
- Gastric Cancer
- Pancreatic Cancer
- Breast Cancer
- others
- Europe CAR-T cell therapy treatment MARKET, BY end user
- overview
- hospitals
- Specialty Clinics
- others
- Europe CAR-T cell therapy treatment MARKET, BY distribution channel
- overview
- hospital Pharmacy
- others
- Europe CAR-T cell therapy treatment market by geography
- EUROPE
- germany
- u.k
- France
- Italy
- Spain
- NETHERLANDS
- Russia
- Switzerland
- Belgium
- Turkey
- Austria
- Norway
- Hungary
- Lithuania
- Ireland
- Poland
- Rest of Europe
- Europe CAR-T Cell Therapy Treatment Market: COMPANY landscape
- company share analysis: europe
- swot analysis
- company profile
- kite pharma (A subsidiary of GILEAD SCIENCES, INC.)
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- company share analysis
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Novartis AG
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- company share analysis
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Abbvie inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Adaptimmune Therapeutics plc
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Amgen Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Atara Biotherapeutics, Inc.
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- aurora biopharmA
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Autolus
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Bellicum Phamaceuticals, Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- BioAtla Inc.
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- bluebird bio, inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Bristol-Myers Squibb Company
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- carina biotech
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- cartherics pty ltd
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- cartesian therapeutics, inc.
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- cellectis SA
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- celyad oncology SA
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Johnson & Johnson Services, Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- sorrento therapeutics, INC.
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- tc biopharm Limited
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- tessa therapeutics ltd.
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- tmunity therapeutics
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- mustang bio
- COMPANY SNAPSHOT
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Xyphos (A Subsidiary of Astellas Pharma Inc.)
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PIPELINE PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- ziopharm oncology, inc.
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- questionnaire
- related reports
Lista de Tabela
TABLE 1 Europe CAR-T cell therapy treatment Market, pipeline analysis
TABLE 2 Below provided are the alternative chemotherapies of CAR-T cell therapy:
TABLE 3 TOTAL HEALTH SPENDING BY THE U.S. (2015-2016)
TABLE 4 Europe CAR-T CELL THERAPY TREATMENTMarket, By MOLECULE, 2019-2028 (USD Million)
TABLE 5 Europe Autologous CAR-T Cells in CAR-T CELL THERAPY TREATMENTMarket, By Region, 2017-2028 (USD Million)
TABLE 6 Europe Allogeneic CAR-T Cells in CAR-T CELL THERAPY TREATMENTMARKET, By Region, 2019-2028 (USD Million)
TABLE 7 Europe CAR-T CELL THERAPY TREATMENTMarket, By Structure, 2019-2028 (USD Million)
Celyad is engaged in the manufacturing of CYAD-211, a first generation CAR-T cell therapy expressing BCMA targeting chimeric antigen receptor which interferes with the expression of the CD3ζ of T cell receptor complex.
TABLE 8 Europe First Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 9 Europe Second Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 10 Europe Third Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 11 Europe Third Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 12 Europe CAR-T CELL THERAPY TREATMENTMarket, By targeted antigens, 2019-2028 (USD Million)
TABLE 13 Europe Antigens on Hematologic Malignancies in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)
TABLE 14 Europe Antigens on Hematologic Malignancies in CAR-T CELL THERAPY TREATMENT Market, By Antigens on Hematologic Malignancies, 2019-2028 (USD Million)
TABLE 15 Europe Antigens on Solid Tumors in CAR-T CELL THERAPY TREATMENTMarket , By Region, 2017-2028 (USD Million)
TABLE 16 Europe Antigens on Solid Tumors in CAR-T CELL THERAPY TREATMENT Market, By Antigens on Solid Tumors, 2019-2028 (USD Million)
TABLE 17 Europe others in CAR-T CELL THERAPY TREATMENTMarket , By Region, 2017-2028 (USD Million)
TABLE 18 Europe YESCARTA in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 19 Europe YESCARTA in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 20 Europe KYMRIAH in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 21 Europe TECARTUS in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 22 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 23 Europe CAR-T cell therapy treatment Market, By therapeutic type, 2019-2028 (USD Million)
TABLE 24 Europe Follicular Lymphoma in CAR-T cell therapy treatment Market, By therapeutic type, 2017-2028 (USD Million)
TABLE 25 Europe Diffuse Large B-Cell Lymphoma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 26 Europe ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 27 Europe Mantle Cell Lymphoma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 28 Europe Multiple Myeloma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 29 Europe hematologic malignancies in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 30 Europe hematologic malignancies on Solid Tumors in CAR-T CELL THERAPY TREATMENT Market, By therapeutic application, 2019-2028 (USD Million)
TABLE 31 Europe Lung Cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 32 Europe chronic lymphocytic leukemia in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 33 Europe gastric cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 34 Europe pancreatic cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 35 Europe breast cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 36 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 37 Europe CAR-T cell therapy treatment Market, By END USER, 2019-2028 (USD Million)
TABLE 38 Europe hospitals in CAR-T cell therapy treatment Market, By therapeutic type, 2017-2028 (USD Million)
TABLE 39 Europe specialty clinics in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 40 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 41 Europe CAR-T cell therapy treatment Market, By distribution channel, 2019-2028 (USD Million)
TABLE 42 Europe hospital pharmacy in CAR-T cell therapy treatment Market, By distribution channel, 2017-2028 (USD Million)
TABLE 43 Europe others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)
TABLE 44 Europe CAR-T Cell Therapy Treatment Market, By Region, 2019-2028 (USD Million)
TABLE 45 Europe CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 46 Europe CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 47 Europe CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 48 europe Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 49 Europe Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 50 Europe CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 51 Europe CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 52 Europe Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 53 Europe CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 54 Europe CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 55 Germany CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 56 Germany CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 57 Germany CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 58 Germany Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 59 Germany Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 60 Germany CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 61 Germany CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 62 Germany Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 63 Germany CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 64 Germany CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 65 U.K CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 66 U.K CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 67 U.K CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 68 U.K Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 69 U.K Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 70 U.K CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 71 U.K CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 72 U.K Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 73 U.K CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 74 U.K CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 75 FRANCE CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 76 FRANCE CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 77 FRANCE CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 78 FRANCE Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 79 FRANCE Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 80 FRANCE CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 81 FRANCE CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 82 FRANCE Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 83 FRANCE CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 84 FRANCE CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 85 ITALY CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 86 ITALY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 87 ITALY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 88 ITALY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 89 ITALY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 90 ITALY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 91 ITALY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 92 ITALY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 93 ITALY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 94 ITALY CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 95 Spain CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 96 SPAIN CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 97 SPAIN CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 98 SPAIN Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 99 SPAIN Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 100 SPAIN CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 101 SPAIN CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 102 SPAIN Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 103 SPAIN CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 104 SPAIN CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 105 netherlands CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 106 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 107 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 108 NETHERLANDS Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 109 NETHERLANDS Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 110 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 111 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 112 NETHERLANDS Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 113 NETHERLANDS CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 114 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 115 Russia CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 116 RUSSIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 117 RUSSIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 118 RUSSIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 119 RUSSIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 120 RUSSIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 121 RUSSIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 122 RUSSIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 123 RUSSIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 124 RUSSIA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 125 Switzerland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 126 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 127 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 128 SWITZERLAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 129 SWITZERLAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 130 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 131 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 132 SWITZERLAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 133 SWITZERLAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 134 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 135 belgium CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 136 BELGIUM CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 137 BELGIUM CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 138 BELGIUM Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 139 BELGIUM Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 140 BELGIUM CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 141 BELGIUM CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 142 BELGIUM Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 143 BELGIUM CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 144 BELGIUM CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 145 turkey CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 146 TURKEY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 147 TURKEY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 148 TURKEY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 149 TURKEY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 150 TURKEY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 151 TURKEY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 152 TURKEY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 153 TURKEY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 154 turkey CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 155 Austria CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 156 AUSTRIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 157 AUSTRIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 158 AUSTRIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 159 AUSTRIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 160 AUSTRIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 161 AUSTRIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 162 AUSTRIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 163 AUSTRIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 164 Austria CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 165 norway CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 166 NORWAY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 167 NORWAY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 168 NORWAY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 169 NORWAY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 170 NORWAY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 171 NORWAY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 172 NORWAY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 173 NORWAY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 174 Norway CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 175 Hungary CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 176 HUNGARY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 177 HUNGARY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 178 HUNGARY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 179 HUNGARY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 180 HUNGARY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 181 HUNGARY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 182 HUNGARY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 183 HUNGARY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 184 Hungary CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 185 Lithuania CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 186 LITHUANIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 187 LITHUANIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 188 LITHUANIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 189 LITHUANIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 190 LITHUANIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 191 LITHUANIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 192 LITHUANIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 193 LITHUANIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 194 Lithuania CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 195 Ireland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 196 IRELAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 197 IRELAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 198 IRELAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 199 IRELAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 200 IRELAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 201 IRELAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 202 IRELAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 203 IRELAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 204 ireland CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 205 Poland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
TABLE 206 POLAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)
TABLE 207 POLAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 208 POLAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 209 POLAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)
TABLE 210 POLAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)
TABLE 211 POLAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 212 POLAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)
TABLE 213 POLAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)
TABLE 214 Poland CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 215 Rest of Europe CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)
Lista de Figura
FIGURE 1 Europe CAR-T cell therapy treatment MARKET: SEGMENTATION
FIGURE 2 EUROPE CAR-T cell therapy treatment MARKET: DATA TRIANGULATION
FIGURE 3 Europe CAR-T cell therapy treatment Market: DROC ANALYSIS
FIGURE 4 Europe CAR-T cell therapy treatment market: Europe VS REGIONAL MARKET ANALYSIS
FIGURE 5 Europe CAR-T cell therapy treatment Market: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE CAR-T cell therapy treatment MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE CAR-T cell therapy treatment MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE CAR-T cell therapy treatment MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE CAR-T cell therapy treatment MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE car-t cell therapy treatment MARKET: MARKET product COVERAGE GRID
FIGURE 11 Europe car-t cell therapy treatment market: SEGMENTATION
FIGURE 12 increasing investment in research and development is expected to drive THE Europe CAR-T cell therapy treatment market IN THE FORECAST PERIOD OF 2021 to 2028
FIGURE 13 Autologus car-t cells SEGMENT is expected to account for the largest share of the Europe CAR-T CELL THERAPY TREATMENT market in 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGEs OF Europe CAR-T cell therapy treatment Market
FIGURE 15 New Cancer Cases Worldwide, (2018)
FIGURE 16 Europe Cancer Incidence (2018)
FIGURE 17 Cancer Death By Type (in million), world, 2017
FIGURE 18 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, 2021
FIGURE 19 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, 2019-2028 (USD Million)
FIGURE 20 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, CAGR (2021-2028)
FIGURE 21 Europe CAR-T CELL THERAPY TREATMENTmarket: BY Product, LIFELINE CURVE
FIGURE 22 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, 2021
FIGURE 23 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, 2019-2028 (USD Million)
FIGURE 24 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, CAGR (2021-2028)
FIGURE 25 Europe CAR-T CELL THERAPY TREATMENTmarket: BY structure, LIFELINE CURVE
FIGURE 26 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, 2021
FIGURE 27 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, 2019-2028 (USD Million)
FIGURE 28 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, CAGR (2021-2028)
FIGURE 29 Europe CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, LIFELINE CURVE
FIGURE 30 Europe CAR-T cell therapy treatment market: BY brand, 2020
FIGURE 31 Europe CAR-T cell therapy treatment market: BY brand, 2020-2028 (USD Million)
FIGURE 32 Europe CAR-T cell therapy treatment market: BY brand, CAGR (2020-2028)
FIGURE 33 Europe CAR-T cell therapy treatment market: BY brand, LIFELINE CURVE
FIGURE 34 Europe CAR-T cell therapy treatment market: BY therapeutic application, 2020
FIGURE 35 Europe CAR-T cell therapy treatment market: BY therapeutic application, 2020-2028 (USD Million)
FIGURE 36 Europe CAR-T cell therapy treatment market: BY therapeutic application, CAGR (2020-2028)
FIGURE 37 Europe CAR-T cell therapy treatment market: BY therapeutic application, LIFELINE CURVE
FIGURE 38 Europe CAR-T cell therapy treatment market: BY END USER, 2020
FIGURE 39 Europe CAR-T cell therapy treatment market: BY END USER, 2020-2028 (USD Million)
FIGURE 40 Europe CAR-T cell therapy treatment market: BY END USER, CAGR (2020-2028)
FIGURE 41 Europe CAR-T cell therapy treatment market: BY END USER, LIFELINE CURVE
FIGURE 42 Europe CAR-T cell therapy treatment market: BY distribution channel, 2020
FIGURE 43 Europe CAR-T cell therapy treatment market: BY distribution channel, 2020-2028 (USD Million)
FIGURE 44 Europe CAR-T cell therapy treatment market: BY distribution channel, CAGR (2020-2028)
FIGURE 45 Europe CAR-T cell therapy treatment market: BY distribution channel, LIFELINE CURVE
FIGURE 46 Europe CAR-T CELL THERAPY TREATMENT market: SNAPSHOT (2020)
FIGURE 47 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020)
FIGURE 48 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2021 & 2028)
FIGURE 49 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020 & 2028)
FIGURE 50 Europe CAR-T CELL THERAPY TREATMENT market: BY product (2021-2028)
FIGURE 51 EUROPE CAR-T Cell Therapy Treatment Market: company share 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
